Vickie E. Baracos researcher
Baracos, Vickie E.
VIAF ID: 315223681 (Personal)
Permalink: http://viaf.org/viaf/315223681
Preferred Forms
- 100 1 _ ‡a Baracos, Vickie E
-
- 100 0 _ ‡a Vickie E. Baracos ‡c researcher
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer | |
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. | |
Dénutrition en cancérologie : quand demander un avis spécialisé ? | |
The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival | |
Development and psychometric testing of the Adaptive Capacity Index, an instrument to measure adaptive capacity in individuals with advanced cancer | |
Drug utilization review on a tertiary palliative care unit | |
Effect of Escherichia coli infection on growth and protein metabolism in broiler chicks (Gallus domesticus). | |
Effects of exercise training on antitumor efficacy of doxorubicin in MDA-MB-231 breast cancer xenografts. | |
Effects of sample size on differential gene expression, rank order and prediction accuracy of a gene signature | |
The emerging role of computerized tomography in assessing cancer cachexia | |
Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy | |
Evolving classification systems for cancer cachexia: ready for clinical practice? | |
An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. | |
Expression and activity of matrix metallo proteinases 2 and 9 and their inhibitors in rat lungs during the perinatal period and in diaphragmatic hernia | |
FEM-based automatic segmentation of muscle and fat tissues from thoracic CT images | |
Functional body composition and related aspects in research on obesity and cachexia: report on the 12th Stock Conference held on 6 and 7 September 2013 in Hamburg, Germany | |
Glutamine supplementation influences immune development in the newly weaned piglet | |
The head and neck symptom checklist©: an instrument to evaluate nutrition impact symptoms effect on energy intake and weight loss | |
Home-based functional walking program for advanced cancer patients receiving palliative care: a case series | |
Hypercatabolism and hypermetabolism in wasting states | |
An in vitro preparation of the extensor digitorum communis muscle from the chick (Gallus domesticus) for studies of protein turnover | |
Insulin-like growth factor-1 and insulin resistance in skeletal muscles of adult and old rats | |
An invitation to the 2nd Cancer Cachexia Conference, Montréal, Canada | |
Is there a genetic cause of appetite loss?-an explorative study in 1,853 cancer patients | |
Is there a human homologue to the murine proteolysis-inducing factor? | |
Loss of adipose tissue and plasma phospholipids: Relationship to survival in advanced cancer patients | |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma | |
Low skeletal muscle is associated with toxicity in patients included in phase I trials | |
MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis | |
Malnutrition assessment in patients with cancers of the head and neck: a call to action and consensus | |
The management of anorexia by patients with advanced cancer: a critical review of the literature | |
Measurement of skeletal muscle radiation attenuation and basis of its biological variation | |
Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: Interrelations and associations with prognosis | |
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression | |
Muscle wasting | |
n-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. | |
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. | |
Nowa rola tomografii komputerowej w ocenie wyniszczenia nowotworowego | |
Nutrition modulation of gastrointestinal toxicity related to cancer chemotherapy: from preclinical findings to clinical strategy | |
The nutrition swing | |
Nutritional modulation of antitumor efficacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor | |
Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results | |
Ornithine α-ketoglutarate limits muscle protein breakdown without stimulating tumor growth in rats bearing Yoshida ascites hepatoma | |
P-selectin genotype is associated with the development of cancer cachexia | |
Parenteral nutrition in advanced cancer: indications and clinical practice guidelines | |
Physical activity interests and preferences in palliative cancer patients | |
Pitfalls in defining and quantifying cachexia | |
Plasma and neutrophil fatty acid composition in advanced cancer patients and response to fish oil supplementation. | |
Poor Physical Function as a Marker of Sarcopenic Obesity in Adults with Class II/III Obesity | |
Prediction of skeletal muscle and fat mass in patients with advanced cancer using a metabolomic approach | |
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study | |
Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction | |
A proinflammatory tumor that activates protein degradation sensitizes rats to catabolic effects of endotoxin | |
Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy | |
Protein Metabolism in Cachectic Tumor-Bearing Rats: Effect of Tumor Excision | |
The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer | |
Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway | |
Reduced splenocyte metabolism and immune function in rats implanted with the Morris hepatoma 7777 | |
Reframing eating during chemotherapy in cancer patients with chemosensory alterations. | |
Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia | |
The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats | |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment | |
Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma | |
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer | |
Sarcopenia is a predictor of outcomes in very elderly patients undergoing emergency surgery | |
Sarcopenia with limited mobility: an international consensus | |
Severe muscle depletion in patients on the liver transplant wait list: Its prevalence and independent prognostic value | |
Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation | |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing War | |
Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma | |
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies | |
Skeletal muscle protein mobilization during the progression of lactation | |
Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer | |
Synthesis and evaluation of fluorobenzoylated di- and tripeptides as inhibitors of cyclooxygenase-2 (COX-2) | |
Too little or too much are inadequate | |
Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia | |
Understanding the mechanisms and treatment options in cancer cachexia | |
USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states | |
A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands | |
Would you buy a new tool to improve your practice? |